Loading clinical trials...

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

NCT02429271•Hellenic Cardiovascular Research Society

View on ClinicalTrials.gov

Summary

This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial infarction and ST segment elevation after thrombolysis.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Provision of informed consent prior to any study specific procedures.
•2. Male and female subjects, 18-75 years of age (both inclusive).
•3. STEMI eligible for thrombolysis
•4. Inability to perform primary PCI, because of transport time in centers carrying out primary PCI lasting more than two hours
•5. Ability of transportation in 3-24 hours after thrombolysis in order to perform coronary angiography and PCI. This period may be extended for reasons of extreme importance up to 72 hours at the latest.

Exclusion Criteria

•1. Inability to give informed consent.
•2. Pre-treatment with any inhibitor of the purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) within the 7-day period prior to randomization.
•3. Cardiogenic shock - according to Killip classification - class 4.
•4. Suspicion or evidence of mechanical complication, including mitral valve dysfunction, ventricular septal rupture, and rupture of the left ventricle.
•5. Current use of warfarin or other anticoagulant drug.
•6. Known multivessel coronary artery disease not suitable for revascularization.
•7. Any contraindication to thrombolytic therapy -Central nervous system damage or neoplasms or atrioventricular malformation -Recent major trauma/surgery/head injury (within the preceding 3 weeks) -Gastrointestinal bleeding within the past month -Known bleeding disorder (excluding menses) -Aortic dissection -Non-compressible punctures in the past 24 hours (e.g. liver biopsy, lumbar puncture).
•8. Other bleeding diathesis, or considered by Investigator to be at high risk for bleeding.
•9. Any kind of stroke in the past year or haemorrhagic stroke ever.
•10. Severe uncontrolled hypertension (\>180/110 mmHg) prior to randomisation.
+15 more criteria

Locations (1)

General Hospital of Heraklion Venizeleio-Pananeio

Heraklion, Crete, Greece

Key Dates

Start Date

August 1, 2015

Primary Completion Date

February 1, 2019

Completion Date

February 1, 2019

Last Updated

November 22, 2019

Enrollment

336

ACTUAL participants

Conditions

Myocardial InfarctionST Segment Elevation Myocardial Infarction (STEMI)

Interventions

Ticagrelor

DRUG

Clopidogrel

DRUG

Percutaneous Coronary Intervention (PCI)

PROCEDURE

Coronary Angiography

PROCEDURE

Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.

NCT05198791

Myocardial Infarction, AcuteMyocardial Infarction With Nonobstructive Coronary Arteries+1 more

View study

RECRUITINGNA

Fast Discharge After Acute Myocardial Infarction Discharge MI

NCT06744322

Acute Myocardial Infarction (AMI)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 22, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

Inclusion Criteria

Exclusion Criteria

Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.

Fast Discharge After Acute Myocardial Infarction Discharge MI

A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack

Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone

SuperSaturated Oxygen Comprehensive Observational Registry

Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease